The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201.
 
Heather Landau
Consulting or Advisory Role - Abbvie/Genentech; Nexcella; Prothena
Research Funding - Alexion Pharmaceuticals (Inst); Janssen Oncology (Inst); Nexcella (Inst); Protego Biopharma (Inst); Prothena (Inst)
 
Charlotte Hughes
No Relationships to Disclose
 
Aaron Rosenberg
No Relationships to Disclose
 
Mehrdad Abedi
No Relationships to Disclose
 
Shahzad Raza
Honoraria - Cancer Experts Now; Deerfield Management; Doximity; Guidepoint Global; techspert.io; Zoom Rx (Market research)
Consulting or Advisory Role - Prothena
Research Funding - Janssen (Inst); Nexcella (Inst)
 
Jeffrey Zonder
Employment - Bristol-Myers Squibb/Celgene (I)
Consulting or Advisory Role - Sanofi/Regeneron; Takeda
Research Funding - BMS (Inst); Janssen Oncology
 
Eugene Brailovski
No Relationships to Disclose
 
Sergio Giralt
Honoraria - Amgen; Jazz Pharmaceuticals; Sanofi
Consulting or Advisory Role - Actinuum; Amgen; Bristol-Myers Squibb; Incyte; Janssen; Jazz Pharmaceuticals; Johnson & Johnson; Pfizer; Sanofi
Research Funding - Actinuum; Amgen; Celgene (Inst); Johnson & Johnson; Miltenyi Biotec (Inst); Sanofi
Travel, Accommodations, Expenses - Amgen; Celgene; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Sanofi
 
Sham Mailankody
Honoraria - OncLive/MJH Life Sciences; Physicans' Education Resource; Plexus
Consulting or Advisory Role - Abbvie; Arcellx; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Galapagos UK; Janssen Oncology; Legend Biotech; Optum; Optum
Research Funding - Alimera Sciences (Inst); Bristol-Myers Squibb (Inst); Caribou Biosciences; Fate Therapeutics; Fate Therapeutics; Janssen Oncology (Inst); Juno Therapeutics (Inst); Takeda (Inst)
 
Jae Park
Stock and Other Ownership Interests - Curocell
Consulting or Advisory Role - Adaptive Biotechnologies; AffyImmune Therapeutics; Allogene Therapeutics; Amgen; Artiva; Autolus; Be Biopharma; BeiGene; Bristol-Myers Squibb/Celgene/Juno; Caribou Biosciences; Galapagos UK; GC Cell; In8Bio; Intellia Therapeutics; Kite, a Gilead company; Kura Oncology; Minerva Biotechnologies; Novartis; Pfizer; Precision Biosciences; SERVIER; SOBI; Synthekine; Takeda
Research Funding - Autolus Therapeutics (Inst); Caribou Biosciences (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Incyte (Inst); Takeda (Inst)
 
Miguel-Angel Perales
Stock and Other Ownership Interests - NexImmune; Omeros; Orca Bio
Consulting or Advisory Role - Adicet Bio; Allogene Therapeutics; AlloVir; Bristol-Myers Squibb; Caribou Biosciences; Celgene; Cidara Therapeutics; Equillium; Exivir; Incyte; Kite/Gilead; Medigene; Merck; Nektar; NexImmune; Novartis; Omeros; Sanofi; Vor Biopharma
Research Funding - Incyte (Inst); Kite, a Gilead company (Inst); Miltenyi Biotec (Inst); Nektar (Inst); Novartis (Inst)
 
Saad Usmani
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb/Celgene; Genentech; GlaxoSmithKline; Janssen Oncology; Oricell Therapeutics; Regeneron
Research Funding - Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Gracell Therapeutics; Janssen Oncology; K36 Therapeutics
 
David Marks
Employment - Immix BioPharma
Leadership - Immix BioPharma
 
Raymond Comenzo
No Relationships to Disclose
 
Sridevi Rajeeve
No Relationships to Disclose
 
Jennifer Liu
Consulting or Advisory Role - Bay Labs; cytel; Pfizer
Speakers' Bureau - GE Healthcare